Kinetic scheduling of vincristine (NSC-67574) and bleomycin (NSC-125066) in patients with lung cancer and other malignant tumors

R. B. Livingston, G. P. Bodey, J. A. Gottlieb, E. Frei

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Forty eight patients received vincristine and bleomycin given in sequential combination. Of 32 evaluable patients, nine had a partial response (28%) including four of 15 with lung cancer (27%) and three of nine with head and neck cancer (33%). The results of sequential combination therapy in lung cancer appear to be superior to those previously reported for bleomycin alone. Toxicity of the combination was no greater than that expected of each agent. There was no significant myelosuppression.

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalCANCER CHEMOTHER.REP.
Volume57
Issue number2
StatePublished - Dec 1 1973

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this